Finding the needle in the haystack: why high-throughput screening is good for your health.

Abstract:

:High-throughput screening is an essential component of the toolbox of modern technologies that improve speed and efficiency in contemporary cancer drug development. This is particularly important as we seek to exploit, for maximum therapeutic benefit, the large number of new molecular targets emerging from the Human Genome Project and cancer genomics. Screening of diverse collections of low molecular weight compounds plays a key role in providing chemical starting points for iterative optimisation by medicinal chemistry. Examples of successful drug discovery programmes based on high-throughput screening are described, and these offer potential in the treatment of breast cancer and other malignancies.

journal_name

Breast Cancer Res

authors

Aherne GW,McDonald E,Workman P

doi

10.1186/bcr440

keywords:

subject

Has Abstract

pub_date

2002-01-01 00:00:00

pages

148-54

issue

4

eissn

1465-5411

issn

1465-542X

journal_volume

4

pub_type

社论
  • Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study.

    abstract:INTRODUCTION:Laboratory and epidemiologic studies have suggested a modifying effect of cardiac glycosides (for example, digoxin and digitoxin) on cancer risk. We explored the association between digoxin treatment and invasive breast cancer incidence among postmenopausal Danish women. METHODS:We used Danish registries ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2205

    authors: Ahern TP,Lash TL,Sørensen HT,Pedersen L

    更新日期:2008-01-01 00:00:00

  • Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors.

    abstract:INTRODUCTION:Triple-negative breast cancer (TNBC), a subtype of breast cancer with negative expressions of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2), is frequently diagnosed in younger women and has poor prognosis for disease-free and overall survival. Due to the lack...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3575

    authors: Chen YJ,Yeh MH,Yu MC,Wei YL,Chen WS,Chen JY,Shih CY,Tu CY,Chen CH,Hsia TC,Chien PH,Liu SH,Yu YL,Huang WC

    更新日期:2013-11-12 00:00:00

  • The CD44+/CD24- phenotype is enriched in basal-like breast tumors.

    abstract:INTRODUCTION:Human breast tumors are heterogeneous and consist of phenotypically diverse cells. Breast cancer cells with a CD44+/CD24- phenotype have been suggested to have tumor-initiating properties with stem cell-like and invasive features, although it is unclear whether their presence within a tumor has clinical im...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2108

    authors: Honeth G,Bendahl PO,Ringnér M,Saal LH,Gruvberger-Saal SK,Lövgren K,Grabau D,Fernö M,Borg A,Hegardt C

    更新日期:2008-01-01 00:00:00

  • Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression.

    abstract::Recent insights into the molecular and cellular mechanisms underlying cancer development have revealed that immune cells functionally regulate epithelial cancer development and progression. Moreover, accumulated clinical and experimental data indicate that the outcome of an immune response toward an evolving breast ne...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr1746

    authors: DeNardo DG,Coussens LM

    更新日期:2007-01-01 00:00:00

  • Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism.

    abstract:INTRODUCTION:Human epidermal growth factor 2 (Her2), a receptor tyrosine kinase, is overexpressed in breast cancers. It has been successfully targeted by small molecule kinase inhibitors and by antibodies. Recent clinical data show a synergistic response in patients when two antibodies, trastuzumab and pertuzumab, are ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2888

    authors: Fuentes G,Scaltriti M,Baselga J,Verma CS

    更新日期:2011-05-22 00:00:00

  • CD24(+) cells fuel rapid tumor growth and display high metastatic capacity.

    abstract:INTRODUCTION:Breast tumors are comprised of distinct cancer cell populations which differ in their tumorigenic and metastatic capacity. Characterization of cell surface markers enables investigators to distinguish between cancer stem cells and their counterparts. CD24 is a well-known cell surface marker for mammary epi...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0589-9

    authors: Rostoker R,Abelson S,Genkin I,Ben-Shmuel S,Sachidanandam R,Scheinman EJ,Bitton-Worms K,Orr ZS,Caspi A,Tzukerman M,LeRoith D

    更新日期:2015-06-04 00:00:00

  • A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women.

    abstract:BACKGROUND:MicroRNAs (miRNAs) regulate gene expression and influence cancer. Primary transcripts of miRNAs (pri-miRNAs) are poorly annotated and little is known about the role of germline variation in miRNA genes and breast cancer (BC). We sought to identify germline miRNA variants associated with BC risk and tumor sub...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-018-0964-4

    authors: Bensen JT,Graff M,Young KL,Sethupathy P,Parker J,Pecot CV,Currin K,Haddad SA,Ruiz-Narváez EA,Haiman CA,Hong CC,Sucheston-Campbell LE,Zhu Q,Liu S,Yao S,Bandera EV,Rosenberg L,Lunetta KL,Ambrosone CB,Palmer JR,Troes

    更新日期:2018-06-05 00:00:00

  • Breast cancer incidence and case fatality among 4.7 million women in relation to social and ethnic background: a population-based cohort study.

    abstract:INTRODUCTION:Incidence of breast cancer is increasing around the world and it is still the leading cause of cancer mortality in low- and middle-income countries. We utilized Swedish nationwide registers to study breast cancer incidence and case fatality to disentangle the effect of socioeconomic position (SEP) and immi...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3086

    authors: Beiki O,Hall P,Ekbom A,Moradi T

    更新日期:2012-01-06 00:00:00

  • Hormonal control of p53 and chemoprevention.

    abstract::Improvements in the detection and treatment of breast cancer have dramatically altered its clinical course and outcome. However, prevention of breast cancer remains an elusive goal. Parity, age of menarche, and age at menopause are major risk factors drawing attention to the important role of the endocrine system in d...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr431

    authors: Jerry DJ,Minter LM,Becker KA,Blackburn AC

    更新日期:2002-01-01 00:00:00

  • Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer.

    abstract:INTRODUCTION:Hypoxia-inducible factor (HIF)-1alpha levels in invasive breast carcinoma have been shown to be an adverse prognostic indicator. Cellular HIF-1alpha activity is regulated by factor-inhibiting hypoxia-inducible factor 1 (FIH-1). In hypoxia, FIH-1 hydroxylation of Asn803 within the C-terminal transactivation...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1838

    authors: Tan EY,Campo L,Han C,Turley H,Pezzella F,Gatter KC,Harris AL,Fox SB

    更新日期:2007-01-01 00:00:00

  • Tyrosine kinase signalling in breast cancer: modulation of tyrosine kinase signalling in human breast cancer through altered expression of signalling intermediates.

    abstract::The past decade has seen the definition of key signalling pathways downstream of receptor tyrosine kinases (RTKs) in terms of their components and the protein-protein interactions that facilitate signal transduction. Given the strong evidence that links signalling by certain families of RTKs to the progression of brea...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr54

    authors: Kairouz R,Daly RJ

    更新日期:2000-01-01 00:00:00

  • Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members.

    abstract::ErbB (also termed HER) receptors are expressed in various tissues of epithelial, mesenchymal and neuronal origin, in which they are involved in the control of diverse biological processes such as proliferation, differentiation, migration and apoptosis. Furthermore, their deregulated expression has been implicated in m...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr327

    authors: Olayioye MA

    更新日期:2001-01-01 00:00:00

  • Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study.

    abstract:INTRODUCTION:Radiation exposure at a young age is one of the strongest risk factors for breast cancer. Germline mutations in genes involved in the DNA-damage repair pathway (DDRP) may render women more susceptible to radiation-induced breast cancer. METHODS:We evaluated the contribution of germline mutations in the DD...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1668

    authors: Broeks A,Braaf LM,Huseinovic A,Nooijen A,Urbanus J,Hogervorst FB,Schmidt MK,Klijn JG,Russell NS,Van Leeuwen FE,Van 't Veer LJ

    更新日期:2007-01-01 00:00:00

  • Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions.

    abstract::A series of recent studies have demonstrated that the retinoblastoma tumor suppressor (RB) pathway plays a critical role in multiple clinically relevant aspects of breast cancer biology, spanning early stage lesions to targeted treatment of metastatic disease. In ductal carcinoma in situ, multiple groups have shown th...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr3652

    authors: Witkiewicz AK,Knudsen ES

    更新日期:2014-05-07 00:00:00

  • More breast cancer genes?

    abstract::A new gene associated with a high risk of breast cancer, termed BRCAX, may exist on chromosome 13q. Tumours from multicase Nordic breast cancer families, in which mutations in BRCA1 and BRCA2 had been excluded, were analyzed using comparative genomic hybridization in order to identify a region of interest, which was a...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr290

    authors: Hopper JL

    更新日期:2001-01-01 00:00:00

  • Metastatic breast cancer cells overexpress and secrete miR-218 to regulate type I collagen deposition by osteoblasts.

    abstract:BACKGROUND:Bone is one of the most frequent metastatic sites of advanced breast cancer. Current therapeutic agents aim to inhibit osteoclast-mediated bone resorption but only have palliative effects. During normal bone remodeling, the balance between bone resorption and osteoblast-mediated bone formation is essential f...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-018-1059-y

    authors: Liu X,Cao M,Palomares M,Wu X,Li A,Yan W,Fong MY,Chan WC,Wang SE

    更新日期:2018-10-22 00:00:00

  • The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy.

    abstract::Despite the progress achieved in breast cancer screening and therapeutic innovations, the basal-like subtype of breast cancer (BLBC) still represents a particular clinical challenge. In order to make an impact on survival in this type of aggressive breast cancer, new targeted therapeutic agents are urgently needed. Ab...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr3401

    authors: Hui M,Cazet A,Nair R,Watkins DN,O'Toole SA,Swarbrick A

    更新日期:2013-03-28 00:00:00

  • Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib

    abstract:INTRODUCTION:Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) has been shown to enhance breast cancer cell survival and confer resistance to chemotherapeutic agents. We studied the prognostic and predictive value of PIK3CA mutations a...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-014-0405-y

    authors: Xu B,Guan Z,Shen Z,Tong Z,Jiang Z,Yang J,DeSilvio M,Russo M,Leigh M,Ellis C

    更新日期:2014-07-24 00:00:00

  • Derlin-1 is overexpressed in human breast carcinoma and protects cancer cells from endoplasmic reticulum stress-induced apoptosis.

    abstract:INTRODUCTION:Aberrant microenvironment and endoplasmic reticulum (ER) stress are associated with solid-tumor progression. Stress proteins, like heat shock proteins and glucose-regulated proteins, are frequently overexpressed in human tumors. It has been reported that derlin-1 is involved in ER stress response. In vitro...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1849

    authors: Wang J,Hua H,Ran Y,Zhang H,Liu W,Yang Z,Jiang Y

    更新日期:2008-01-01 00:00:00

  • Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways.

    abstract:INTRODUCTION:Metastasis is the main cause of breast cancer morbidity and mortality. Processes that allow for tumor cell migration and invasion are important therapeutic targets. Here we demonstrate that receptor-interacting protein kinase 2 (RIP2), a kinase known to be involved in inflammatory processes, also has novel...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3629

    authors: Singel SM,Batten K,Cornelius C,Jia G,Fasciani G,Barron SL,Wright WE,Shay JW

    更新日期:2014-03-19 00:00:00

  • Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?

    abstract::Anti-angiogenic therapies have demonstrated their value in the setting of advanced cancer, and are being explored for use in micrometastatic disease. Recent preclinical studies suggest that adjuvant anti-vascular endothelial growth factor (VEGF) therapies may increase the risk of metastasis. How concerning are these p...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2250

    authors: Schneider BP,Sledge GW Jr

    更新日期:2009-01-01 00:00:00

  • Prospective validation of the NCI Breast Cancer Risk Assessment Tool (Gail Model) on 40,000 Australian women.

    abstract:BACKGROUND:There is a growing interest in delivering more personalised, risk-based breast cancer screening protocols. This requires population-level validation of practical models that can stratify women into breast cancer risk groups. Few studies have evaluated the Gail model (NCI Breast Cancer Risk Assessment Tool) i...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-018-1084-x

    authors: Nickson C,Procopio P,Velentzis LS,Carr S,Devereux L,Mann GB,James P,Lee G,Wellard C,Campbell I

    更新日期:2018-12-20 00:00:00

  • Initiating breast cancer by PIK3CA mutation.

    abstract::PIK3CA mutations confer constitutive activation of PI3K, which initiates intracellular kinase signaling cascades that promote cell proliferation and survival. Recent studies by Meyer and colleagues, and Liu and colleagues demonstrate that expression of the H1047R exon 20 mutant of PIK3CA in luminal mammary epithelial ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3103

    authors: Miller TW

    更新日期:2012-02-07 00:00:00

  • The clinical and functional significance of c-Met in breast cancer: a review.

    abstract::c-Met is a receptor tyrosine kinase that upon binding of its ligand, hepatocyte growth factor (HGF), activates downstream pathways with diverse cellular functions that are important in organ development and cancer progression. Anomalous c-Met signalling has been described in a variety of cancer types, and the receptor...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/s13058-015-0547-6

    authors: Ho-Yen CM,Jones JL,Kermorgant S

    更新日期:2015-04-08 00:00:00

  • Update on the use of aromatase inhibitors in early-stage breast cancer.

    abstract::Aromatase inhibitors are currently included in the 'optimal' management of early-stage breast cancer. Uncertainty remains, however, as to the most appropriate treatment strategy, particularly for newly diagnosed women as they seek to trade off the cost, toxicities and efficacy of the treatment options. Recent publicat...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr2410

    authors: Kesisis G,Makris A,Miles D

    更新日期:2009-01-01 00:00:00

  • A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk.

    abstract:BACKGROUND:Breast ductal carcinoma in situ (DCIS) represent approximately 20% of screen-detected breast cancers. The overall risk for DCIS patients treated with breast-conserving surgery stems almost exclusively from local recurrence. Although a mastectomy or adjuvant radiation can reduce recurrence risk, there are sig...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-019-1165-5

    authors: Klimov S,Miligy IM,Gertych A,Jiang Y,Toss MS,Rida P,Ellis IO,Green A,Krishnamurti U,Rakha EA,Aneja R

    更新日期:2019-07-29 00:00:00

  • Inflammation markers and cognitive performance in breast cancer survivors 20 years after completion of chemotherapy: a cohort study.

    abstract:BACKGROUND:Inflammation is an important candidate mechanism underlying cancer and cancer treatment-related cognitive impairment. We investigated levels of blood cell-based inflammatory markers in breast cancer survivors on average 20 years after chemotherapy and explored the relation between these markers and global co...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-018-1062-3

    authors: van der Willik KD,Koppelmans V,Hauptmann M,Compter A,Ikram MA,Schagen SB

    更新日期:2018-11-15 00:00:00

  • Progesterone receptors--animal models and cell signalling in breast cancer. Diverse activation pathways for the progesterone receptor: possible implications for breast biology and cancer.

    abstract::Progesterone and estradiol, and their nuclear receptors, play essential roles in the physiology of the reproductive tract, the mammary gland and the nervous system. Estrogens have traditionally been considered associated with an increased risk of breast cancer. There is, however, compelling evidence that progesterone ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr539

    authors: Lanari C,Molinolo AA

    更新日期:2002-01-01 00:00:00

  • Polymorphic repeat in AIB1 does not alter breast cancer risk.

    abstract::STATEMENT OF FINDINGS: We assessed the association between a glutamine repeat polymorphism in AIB1 and breast cancer risk in a case-control study (464 cases, 624 controls) nested within the Nurses' Health Study cohort. We observed no association between AIB1 genotype and breast cancer incidence, or specific tumor char...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr82

    authors: Haiman CA,Hankinson SE,Spiegelman D,Colditz GA,Willett WC,Speizer FE,Brown M,Hunter DJ

    更新日期:2000-01-01 00:00:00

  • Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.

    abstract:INTRODUCTION:Bisphosphonates are inhibitors of osteoclast-mediated tumor-stimulated osteolysis, and they have become standard therapy for the management of bone metastases from breast cancer. These drugs can also directly induce growth inhibition and apoptosis of osteotropic cancer cells, including estrogen receptor-po...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1363

    authors: Journe F,Chaboteaux C,Magne N,Duvillier H,Laurent G,Body JJ

    更新日期:2006-01-01 00:00:00